8-K: Veru Reports FY25 Results, Advances Obesity Drug Enobosarm

Veru Inc. announced fiscal year 2025 financial results and significant clinical progress for its enobosarm obesity program, including FDA regulatory clarity and plans for a new Phase 2b study.

Summary

• Fiscal Year 2025 net loss decreased to $22.7 million ($1.55 per share) from $37.8 million ($2.80 per share) in FY2024.
• Operating loss from continuing operations decreased to $24.8 million from $36.2 million in FY2024.
• Positive Phase 2b QUALITY study results for enobosarm in combination with GLP-1 RA (semaglutide) showed 100% average preservation of total lean mass and 12% greater fat loss with the 3mg dose at 16 weeks.
• Enobosarm 3mg monotherapy significantly reduced body weight regained by 46% after semaglutide discontinuation in the maintenance extension study.
• The FDA provided regulatory clarity for enobosarm, confirming incremental weight loss as an acceptable primary endpoint and 3mg as an acceptable dosage for future development.
• The company plans to initiate the Phase 2b PLATEAU clinical study in calendar Q1 2026, with interim analysis results anticipated in calendar Q1 2027.
• Post fiscal year end, the company completed a public offering for additional net cash proceeds of approximately $23.4 million.

Sentiment

Score: 8

Explanation: The company reported significantly improved financial losses year-over-year and achieved critical positive clinical trial results and regulatory clarity for its lead obesity drug candidate, enobosarm. The successful capital raise further strengthens its position for upcoming clinical trials. While still operating at a loss and facing future development risks, the progress is highly positive for a late clinical stage biopharmaceutical company.

Positives

• Net loss significantly decreased to $22.7 million in FY2025 from $37.8 million in FY2024.
• Operating loss from continuing operations decreased to $24.8 million in FY2025 from $36.2 million in FY2024.
• Positive topline efficacy and safety results from the Phase 2b QUALITY clinical study for enobosarm.
• Enobosarm 3mg + semaglutide achieved 100% average preservation of total lean mass compared to placebo + semaglutide at 16 weeks.
• Enobosarm 3mg + semaglutide treatment resulted in 12% greater fat loss at 16 weeks.
• In a subset of patients with BMI ≥ 35, enobosarm 3mg + semaglutide showed incremental weight loss (-5.58% vs -4.7% for semaglutide alone) and a higher proportion of patients losing at least 5% body weight (65.4% vs 47.4%).
• Enobosarm 3mg monotherapy reduced body weight regained by 46% after semaglutide discontinuation.
• The FDA provided regulatory clarity, accepting incremental weight loss as a primary endpoint and 3mg as an acceptable dosage for future development.
• A successful public offering post-fiscal year end raised approximately $23.4 million in net cash proceeds.

Negatives

• Cash, cash equivalents, and restricted cash decreased to $15.8 million as of September 30, 2025, from $24.9 million as of September 30, 2024, prior to the recent capital raise.
• Research and development expenses increased to $15.6 million in FY2025 from $12.8 million in FY2024.
• Net loss from discontinued operations increased to $7.0 million in FY2025 from $2.5 million in FY2024.

Risks

• The development of the product portfolio and the results of clinical studies may be unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development.
• The FDA may ultimately disagree that clinical trials support approval, despite prior feedback.
• Inability to reach agreement with the FDA on study design requirements for planned clinical studies, including the Phase 2b program for enobosarm.
• Potential delays in the timing of and results from clinical trials and studies, including due to inability to enroll sufficient subjects or adhere to planned schedules.
• The ability to fund planned clinical development and other operations.
• The timing of any submission to the FDA or any other regulatory authority and any determinations made by them.
• The potential for disruptions at the FDA or other government agencies to negatively affect the business.
• Any products, if approved, may not be commercially successful.
• The ability to obtain sufficient financing, including any partnership or collaboration agreements, on acceptable terms when needed to fund development and operations and to enable the company to continue as a going concern.
• Demand for, market acceptance of, and competition against any products or product candidates.
• New or existing competitors with greater resources and capabilities and new competitive product approvals and/or introductions.
• Changes in regulatory practices or policies or government-driven healthcare reform efforts, including pricing pressures and insurance coverage and reimbursement changes.
• The ability to protect and enforce intellectual property.
• Costs and other effects of litigation, including regulatory challenges, product liability claims, intellectual property, securities litigation, and litigation with the purchaser of the FC2 business.
• The ability to identify, successfully negotiate, and complete suitable acquisitions or other strategic initiatives.
• The ability to successfully integrate acquired businesses, technologies, or products.

Future Outlook

Veru plans to initiate the Phase 2b PLATEAU clinical study in calendar Q1 2026, with interim analysis results anticipated in calendar Q1 2027. This study will evaluate enobosarm 3 mg in approximately 200 older patients (age ≥ 65) with obesity (BMI ≥ 35) who are initiating GLP-1 RA treatment, aiming for clinically meaningful incremental weight reduction and preservation of muscle mass and physical function. The company anticipates that preservation of lean mass and function will lead to increased energy expenditure and further fat reduction in longer clinical studies.

Management Comments

• "The current FDA regulatory guidance for muscle preservation drugs in combination with GLP-1 RA drugs in the treatment of obesity seems particularly well aligned for enobosarm." Mitchell Steiner, M.D., Chairman, President, and Chief Executive Officer of Veru.
• "The FDA defines obesity as a disease of excess body fat, and as such, the medical objective to treat obesity should be to reduce excess body fat, NOT to reduce lean mass." Mitchell Steiner, M.D.
• "The strategy for the next generation of obesity drugs should be a combination therapy with GLP-1 RAs for patients to ONLY lose fat, while preserving lean mass and physical function for a quality weight reduction." Mitchell Steiner, M.D.
• "The completed positive Phase 2b QUALITY clinical trial provided the proof of concept that enobosarm could be that next generation drug in combination with a GLP-1 receptor agonist to make the weight loss journey more selective for only fat while preserving lean mass and physical function in older patients who have obesity lessening the potential risk of loss of balance, and fractures." Mitchell Steiner, M.D.
• "An emerging, common, and serious clinical and therapeutic challenge with GLP-1 RA monotherapy is that 88% of patients with obesity after one year on drug hit a weight loss plateau where they stop losing additional weight while on a GLP-1 RA." Mitchell Steiner, M.D.
• "Enobosarm has been shown to directly burn fat and preserve muscle to increase physical function and burn more calories which could help to break through the weight loss plateau leading to incremental weight reduction." Mitchell Steiner, M.D.

Industry Context

The filing highlights a critical challenge in the rapidly growing GLP-1 RA obesity market: the loss of lean muscle mass and the weight loss plateau experienced by many patients. Veru's enobosarm aims to address this by offering a combination therapy that selectively targets fat loss while preserving muscle and physical function, positioning it as a 'next generation' solution to improve the quality of weight reduction and potentially overcome the plateau effect. This strategy aligns with an evolving understanding of obesity treatment, moving beyond just weight reduction to focus on body composition and functional outcomes, which is a significant trend in the cardiometabolic disease space.

Comparison to Industry Standards

• GLP-1 RA monotherapy (e.g., semaglutide/Wegovy) often leads to significant weight loss but also results in a loss of lean mass (34% lean mass, 66% fat mass in placebo+semaglutide group in QUALITY study) and a decline in physical function (44.8% of patients experienced a ≥10% decline in stair climb power at 16 weeks).
• The SURMOUNT-1 study indicated that 88% of patients on GLP-1 RAs hit a weight loss plateau after one year, with 62.6% still clinically obese. Enobosarm aims to break this plateau.
• Enobosarm 3mg + semaglutide treatment in the QUALITY study resulted in 0% lean mass loss and 100% fat mass loss, a significant improvement in body composition compared to GLP-1 RA monotherapy.
• Enobosarm 3mg treatment reduced the proportion of patients experiencing a ≥10% decline in stair climb power to 17.6%, representing a 59.8% relative reduction compared to semaglutide alone.

Stakeholder Impact

• Shareholders: Positive impact due to reduced net loss, successful clinical trial results, FDA clarity, and a capital raise that funds future development. Potential for significant value creation if enobosarm progresses successfully.
• Patients with Obesity: Potential for a new, more effective treatment option that addresses muscle loss and weight loss plateaus associated with current GLP-1 RA therapies, leading to higher quality weight reduction and improved physical function.
• Investment Professionals: Provides clear data points on clinical progress and financial health, enabling more informed investment decisions.
• Regulatory Authorities: Demonstrates adherence to regulatory processes and progress in addressing unmet medical needs.
• Employees: Continued employment and potential growth opportunities as the company advances its clinical programs.

Next Steps

• Initiate Phase 2b PLATEAU clinical study in calendar Q1 2026.
• Conduct interim analysis for Phase 2b PLATEAU study, with results anticipated in calendar Q1 2027.
• Evaluate enobosarm 3 mg on total body weight, physical function, and safety in approximately 200 patients with obesity (BMI ≥ 35) and older (age ≥ 65) initiating GLP-1 RA treatment.
• Continue to evaluate enobosarm as a muscle preserving and body composition drug, with key secondary endpoints on physical function, mobility disability, patient reported outcomes, total fat mass, total lean mass, and bone mineral density.

Key Dates

Recommendation

The significant reduction in net loss, coupled with highly positive Phase 2b clinical trial results for enobosarm and clear FDA regulatory guidance, de-risks the company's lead asset considerably. The successful capital raise provides funding for the next critical Phase 2b PLATEAU study. Enobosarm addresses a major unmet need in the booming obesity market by preserving lean mass and potentially breaking the weight loss plateau associated with GLP-1 RAs, positioning Veru for substantial future growth and market penetration. The company is advancing a 'next generation' obesity treatment, which could command a premium.

Keywords

Veru Inc., VERU, biopharmaceutical, obesity, enobosarm, GLP-1 RA, semaglutide, weight loss, lean mass preservation, fat loss, Phase 2b QUALITY study, Phase 2b PLATEAU study, FDA regulatory clarity, cardiometabolic diseases, inflammatory diseases, fiscal year 2025 results, clinical trials, drug development, public offering